Not for distribution, directly or indirectly, in or into the United States
This press release shall not, and is not intended to, constitute an offer to sell or an invitation or solicitation of an offer to buy or subscribe for the securities of Peijia Medical Limited in the United States or any other jurisdiction. Securities may not be offered or sold in the United States absent registration under the United States Securities Act of 1933, as amended (the “Securities Act”) or an applicable exemption from the registration requirements of the Securities Act. Any public offering of securities to be made in the United States will be made by means of a prospectus that may be obtained from the issuer or selling security holder and that will contain detailed information about the Company and management, as well as financial statements. The securities referred to herein have not been and will not be registered under the Securities Act or any state securities laws of the United States, or under the applicable securities laws of Australia or Canada. No public offering of the securities referred to herein will be made in the United States or in any jurisdiction outside of Hong Kong. No copy of this press release has been or should be distributed or sent, directly or indirectly, to the United States, its territories or possessions.
This press release contains forward-looking statements and you are cautioned not to place undue reliance on any forward-looking statements contained herein. We can give no assurance that these forward-looking statements will prove to have been correct. Expectations reflected in these forward-looking statements are subject to change and we undertake no obligation and do not intend to update or revise any forward-looking statements herein.

Peijia Medical Successfully Listed on the Main Board of the Stock Exchange of Hong Kong
First Day Closed at HK$25.80, HK$10.44 Higher Than the Offer Price Representing an Increase of approximately 67.97%

(Hong Kong, May 15, 2020) A major domestic player in the high-growth transcatheter valve therapeutic and neurointerventional procedural medical device markets – Peijia Medical Limited (“Peijia Medical” or the “Company”, together with its subsidiaries, the “Group”, stock code: 9996), has successfully listed and commenced dealings on the Main Board of the Stock Exchange of Hong Kong Limited (“Hong Kong Stock Exchange”) today, with a board lot of 1,000 Shares.

The share price closed at HK$25.80 with an intra-day high of HK$27.15 per share, up approximatly 67.97% compared with the offer price. A total of approximately 93.14 million shares were traded, with an aggregate turnover of approximately HK$2.44 billion.

Dr. Yi Zhang, Executive Director, Chairman of the Board, Chief Executive Officer and Chief Technology Officer of Peijia Medical Limited, said, “Getting listed on the Hong Kong Stock Exchange successfully is an important milestone in the Company’s development. We are honored to receive enthusiastic support from all our investors. Standing at a new starting point, we will actively expand our business scale and further strengthen our research and development capabilities. Meanwhile, we plan to expedite the commercialization of our product candidates, expand the product portfolio, and continue to synergize the business and boost operational efficiency. It lays a solid foundation for the long-term development of the Company, with a view to creating fruitful value for our shareholders.”

– End –

About Peijia Medical Limited
Peijia Medical Limited is an active domestic player in both transcatheter valve therapeutic medical device market and neurointerventional procedural medical device market in China. It focuses on the high-growth interventional procedural medical device market in China. Peijia Medical has built a synergetic platform encompassing research and development, manufacturing and commercialization capabilities as well as a set of product portfolio. Reverence for life, perseverance on innovation: Peijia Medical is committed to becoming a widely known medical device company that provides a series of treatment solutions for structural heart and neurovascular diseases.

Issued by Porda Havas International Finance Communications Group for and on behalf of Peijia Medical Limited. For further information, please contact:

Porda Havas International Finance Communications Group
Terence Wong +852 3150 6773 terence.wong@pordahavas.com
Phoenix Fung +852 3150 6786 phoenix.fung@pordahavas.com
Christy Ng +852 3120 6515 christy.ng@pordahavas.com
Renee Zheng +852 3150 6755 r.zheng@pordahavas.com
Yoyo Chan +852 3150 6753 yoyo.chan@pordahavas.com
Fax: +852 3150 6728